Access
To read this story in full you will need to login or make a payment (see right).
News
Nature 403, 582 (10 February 2000) | doi:10.1038/35001204
Biotech companies attack NIH rules
Paul Smaglik
Guidelines on research tools issued recently by the US National Institutes of Health (NIH) came under fire last week from representatives of several small biotechnology companies at a symposium on intellectual property organized by the National Academy of Sciences.The guidelines advise researchers in general who use NIH money to generate tools — such as reagents and new transgenic technologies — against demanding 'reach-through' rights that claim future intellectual property on products generated from a tool's use (see Nature 403, 10; 2000).
To read this story in full you will need to login or make a payment (see right).